CAPRICOR THERAPEUTICS, INC. (CAPR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 10M 20M 30M Q2 '13: 422.8K Q3 '13: 503.2K Q4 '13: 503.2K Q1 '14: 1.3M Q2 '14: 2.2M Q3 '14: 3.4M Q4 '14: 4.8M Q1 '15: 5.5M Q2 '15: 5.8M Q3 '15: 5.8M Q2 '16: 4.8M Q3 '16: 4.2M Q4 '16: 4M Q1 '17: 3.7M Q2 '17: 3.5M Q3 '17: 3.1M Q4 '17: 2.7M Q1 '18: 2.2M Q2 '18: 1.6M Q3 '18: 1.5M Q4 '18: 1.7M Q1 '19: 1.5M Q2 '19: 1.5M Q3 '19: 1.4M Q4 '19: 1M Q1 '20: 960.2K Q2 '20: 599.7K Q3 '20: 474.5K Q4 '20: 310.2K Q1 '21: 165.4K Q2 '21: 319.6K Q3 '21: 302.7K Q4 '21: 244.9K Q2 '23: 9.5M Q3 '23: 14M Q4 '23: 25.2M Q1 '24: 27.1M Q2 '24: 27.2M Q3 '24: 23.2M Q4 '24: 22.3M Q2 '14 Q3 '15 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q3 '23 Q4 '24

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -17.3M Q4 '16: -17M Q1 '17: -16.3M Q2 '17: -15.1M Q3 '17: -12.5M Q4 '17: -12.9M Q1 '18: -13M Q2 '18: -13.8M Q3 '18: -15.3M Q4 '18: -15.3M Q1 '19: -14.2M Q2 '19: -12.1M Q3 '19: -9.6M Q4 '19: -7.7M Q1 '20: -7.3M Q2 '20: -8.7M Q3 '20: -11M Q4 '20: -13.7M Q1 '21: -16.7M Q2 '21: -18.3M Q3 '21: -18.7M Q4 '21: -20.9M Q1 '22: -23.6M Q2 '22: -25.8M Q3 '22: -28M Q4 '22: -29.7M Q1 '23: -30.1M Q2 '23: -30.5M Q3 '23: -30.9M Q4 '23: -24.1M Q1 '24: -26.2M Q2 '24: -30M Q3 '24: -36.1M Q4 '24: -42.6M Q1 '25: -57.3M Q2 '25: -73.4M Q3 '25: -86.7M Q4 '25: -108.1M Q1 '26: -119.9M Q2 '26: -135.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -17.6M Q4 '16: -18.8M Q1 '17: -18.2M Q2 '17: -17M Q3 '17: -14.4M Q4 '17: 2.4M Q1 '18: 2.4M Q2 '18: 1.8M Q3 '18: 374K Q4 '18: -15.2M Q1 '19: -14M Q2 '19: -12M Q3 '19: -9.4M Q4 '19: -7.6M Q1 '20: -7.2M Q2 '20: -8.6M Q3 '20: -10.9M Q4 '20: -13.7M Q1 '21: -16.7M Q2 '21: -18M Q3 '21: -18M Q4 '21: -20M Q1 '22: -22.7M Q2 '22: -25M Q3 '22: -27.5M Q4 '22: -29M Q1 '23: -29M Q2 '23: -29.2M Q3 '23: -29.2M Q4 '23: -22.3M Q1 '24: -24.3M Q2 '24: -27.9M Q3 '24: -34.1M Q4 '24: -40.5M Q1 '25: -55.1M Q2 '25: -70M Q3 '25: -82M Q4 '25: -105M Q1 '26: -114.6M Q2 '26: -129.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -15.2M Q4 '16: -15.1M Q1 '17: -15.6M Q2 '17: -14.4M Q3 '17: -15M Q4 '17: -14.2M Q1 '18: -13M Q2 '18: -13M Q3 '18: -12.8M Q4 '18: -13.9M Q1 '19: -12.1M Q2 '19: -10.1M Q3 '19: -8.8M Q4 '19: -6.8M Q1 '20: -6.4M Q2 '20: -6.7M Q3 '20: -8M Q4 '20: -10.1M Q1 '21: -12.2M Q2 '21: -14.7M Q3 '21: -15M Q4 '21: -16.8M Q1 '22: 10.6M Q2 '22: 8.5M Q3 '22: 6.2M Q4 '22: 4.9M Q1 '23: -14.9M Q2 '23: -17.8M Q3 '23: -20.9M Q4 '23: -25.6M Q1 '24: -31.1M Q2 '24: -33.9M Q3 '24: -36.8M Q4 '24: -40M Q1 '25: -45.2M Q2 '25: -53M Q3 '25: -61M Q4 '25: -69.8M Q1 '26: -92.6M Q2 '26: -104M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -15.3M Q4 '16: -15.2M Q1 '17: -15.7M Q2 '17: -14.5M Q3 '17: -15.2M Q4 '17: -14.3M Q1 '18: -13.2M Q2 '18: -13.2M Q3 '18: -13.1M Q4 '18: -14.2M Q1 '19: -12.2M Q2 '19: -10.3M Q3 '19: -8.8M Q4 '19: -6.8M Q1 '20: -6.4M Q2 '20: -6.8M Q3 '20: -8.3M Q4 '20: -10.6M Q1 '21: -12.8M Q2 '21: -15.5M Q3 '21: -16.1M Q4 '21: -18M Q1 '22: 8.8M Q2 '22: 7M Q3 '22: 4.5M Q4 '22: 2.9M Q1 '23: -16.7M Q2 '23: -19.5M Q3 '23: -22.4M Q4 '23: -26.9M Q1 '24: -32.6M Q2 '24: -35.4M Q3 '24: -38M Q4 '24: -41.2M Q1 '25: -46.6M Q2 '25: -54.7M Q3 '25: -62.8M Q4 '25: -72.7M Q1 '26: -99.8M Q2 '26: -114.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '20: 15.1M Q3 '20: 15.1M Q1 '21: 22.2M Q2 '21: 22.9M Q3 '21: 23.1M Q1 '22: 24.3M Q2 '22: 24.3M Q3 '22: 24.4M Q1 '23: 25.2M Q2 '23: 25.3M Q3 '23: 25.8M Q1 '24: 31.4M Q2 '24: 31.8M Q3 '24: 33.1M Q1 '25: 45.6M Q2 '25: 45.7M Q3 '25: 45.7M Q1 '26: 57.4M Q2 '26: 57.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '16: -1.02 Q4 '16: -1.01 Q1 '17: -0.92 Q2 '17: -0.82 Q3 '17: -0.65 Q4 '17: 0.09 Q1 '18: 0.12 Q2 '18: -1.14 Q3 '18: -2.37 Q4 '18: -3.95 Q1 '19: -4.56 Q2 '19: -3.73 Q3 '19: -2.81 Q4 '19: -2.07 Q1 '20: -1.62 Q2 '20: -1.26 Q3 '20: -1.06 Q4 '20: -1.13 Q1 '21: -1.06 Q2 '21: -1.04 Q3 '21: -0.98 Q4 '21: -0.87 Q1 '22: -0.96 Q2 '22: -1.04 Q3 '22: -1.13 Q4 '22: -1.18 Q1 '23: -1.17 Q2 '23: -1.17 Q3 '23: -1.16 Q4 '23: -0.83 Q1 '24: -0.83 Q2 '24: -0.89 Q3 '24: -1.02 Q4 '24: -1.15 Q1 '25: -1.37 Q2 '25: -1.59 Q3 '25: -1.75 Q4 '25: -2.26 Q1 '26: -2.32 Q2 '26: -2.45 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.